5. Bibliografía

Allen, A. Epigenetic Alterations and Cancer: New Targets for Therapy. IDrugs. 2007;10(10):709-12.

Bostwick, D. G., Gould, V. E., Qian, J., Susani, M., and Marberger, M. Prostate Cancer Detected by UPM3: Radical Prostatectomy Findings. Mod.Pathol. 2006;19(5):630-3.

Brinkman, B. M. Splice Variants As Cancer Biomarkers. Clin Biochem. 2004;37(7):584-94.

Chiang, J. W., Karlan, B. Y., Cass, L., and Baldwin, R. L. BRCA1 Promoter Methylation Predicts Adverse Ovarian Cancer Prognosis. Gynecol.Oncol. 2006;101(3):403-10.

Downes, M. R., Byrne, J. C., Pennington, S. R., Dunn, M. J., Fitzpatrick, J. M., and Watson, R. W. Urinary Markers for Prostate Cancer. BJU.Int. 2007;99(2):263-8

Fradet, Y., Saad, F., Aprikian, A., Dessureault, J., Elhilali, M., Trudel, C., Masse, B., Piche, L., and Chypre, C. UPM3, a New Molecular Urine Test for the Detection of Prostate Cancer. Urology 2004;64(2):311-5.

García-Foncillas, J., Bandrés, E., Zárate, Ruth, and Remírez, Natalia. Proteomic Analysis in Cancer

Cancer Cells. Genes Dev. 1-4-2003;17(7):832-7.

McIver, B., Grebe, S. K., Wang, L., Hay, I. D., and Yokomizo, A. FHIT and TSG101 in Thyroid Tumours: Aberrant Transcripts Reflect Rare Abnormal RNA Processing Events of Uncertain Pathogenetic Clinical Significance. Clin Endocrinol (Oxf) 2000;52(6):749-57.

Ohlsson, G., Moreira, J. M., Gromov, P., Sauter, G., and Celis, J. E. Loss of Expression of the Adipocyte-Type Fatty Acid-Binding Protein (A-FABP) Is Associated With Progression of Human Urothelial Carcinomas. Mol.Cell Proteomics. 2005;4(4):570-81.

Parekh, D. J., Ankerst, D. P., Troyer, D., Srivastava, S., and Thompson, I. M. Biomarkers for Prostate Cancer Detection. J.Urol. 2007;178(6):2252-9.

Polley, A. C., Mulholland, F., Pin, C., Williams, E. A., Bradburn, D. M., Mills, S. J., Mathers, J. C., and Johnson, I. T. Proteomic Analysis Reveals Field-Wide Changes in Protein Expression in the Morphologically Normal Mucosa of Patients With Colorectal Neoplasia. Ca ncer Res. 1-7-2006;66(13):6553-62.

Research: Potential Application in Clinical Use. Clinical & Translational Oncology 2006;(Oncology):250-61.

Gerling, I. C., Solomon, S. S., and Bryer-Ash, M. Genomes, Transcriptomes, and Proteomes: Molecular Medicine and Its Impact on Medical Practice. Arch.Intern.Med. 27-1-2003;163(2):190-8

Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P.,Taube, S., Somerfield, M. R., Hayes, D. F., and Bast, R. C., Jr. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. J.Clin Oncol. 20-11-2007;25(33):5287-312.

Hussain, S. P., Schwank, J., Staib, F., Wang, X. W., and Harris, C. C. TP53 Mutations and Hepatocellular Carcinoma: Insights into the Etiology and Pathogenesis of Liver Cancer. Oncogene 2-4-2007;26(15):2166-76.

Hutchinson, L. M., Chang, E. L., Becker, C. M., Shih, M. C., Brice, M., DeWolf, W. C., Gaston, S. M., and Zetter, B. R. Use of Thymosin Beta15 As a Urinary Biomarker in Human Prostate Cancer. Prostate 1-7-2005;64(2):116-27.

Jiang, M. and Milner, J. Bcl-2 Constitutively Suppresses P53-Dependent Apoptosis in Colorectal

Stevens, E. V., Nishizuka, S., Antony, S., Reimers, M., Varma, S., Young, L., Munson, P. J., Weinstein, J. N., Kohn, E. C., and Pommier, Y. Predicting Cisplatin and Trabectedin Drug Sensitivity in Ovarian and Colon Cancers. Mol.Cancer Ther. 2008;7(1):10-8.

Unwin, R. D. and Whetton, A. D. How Will Haematologists Use Proteomics? Blood Rev. 2007;21(6):315-26.

Woodson, K., O'Reilly, K. J., Hanson, J. C., Nelson, D., Walk, E. L., and Tangrea, J. A. The Usefulness of the Detection of GSTP1 Methylation in Urine As a Biomarker in the Diagnosis of Prostate Cancer. J.Urol. 2008;179(2):508-11.

Yin, J. Q., Gao, J., Shao, R., Tian, W. N., Wang, J., and Wan, Y. SiRNA Agents Inhibit Oncogene Expression and Attenuate Human Tumor Cell Growth. J.Exp.Ther.Oncol. 2003;3(4):194-204.

Zhong, S., Fields, C. R., Su, N., Pan, Y. X., and Robertson, K. D. Pharmacologic Inhibition of Epigenetic Modifications, Coupled With Gene Expression Profiling, Reveals Novel Targets of Aberrant DNA Methylation and Histone Deacetylation in Lung Cancer. Oncogene 19-4-2007;26(18):2621-34